

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER POR PATENTS PO Box 1450 Alcassackin, Virginia 22313-1450 www.nepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/517,805	12/05/2005	Ernesto Menta	200144.413USPC	8932		
500 SEED INTEL	7590 11/18/200 FCTHAL PROPERTY	9 Y LAW GROUP PLLC	EXAM	UNER		
701 FIFTH AVE			DENTZ, B	DENTZ, BERNARD I		
SUITE 5400 SEATTLE, W	A 98104		ART UNIT	PAPER NUMBER		
,			1625			
			MAIL DATE	DELIVERY MODE		
			11/18/2009	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Application No. Applicant(s) 10/517,805 MENTA ET AL. Office Action Summary Examiner Art Unit

Any reply received by the Office		i the maining date of t	nis communication,	even ii umety nieu,	
garned natent term adjustment	See 37 CED 1 704/b)				

	Bernard Dentz	1625	
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence ad	dress
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.3 after SIX (6) MCMTHS from the mailing date of this communication.  1 Failure to reply within the safe or vashende period for reply will by statute. Any reply received by the Office later than these months after the mailing carned patient term adjustment. See 37 CFR 1.70(b).	TE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tim Il apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	I. lely filed the mailing date of this or D (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 21 Au	gust 2009.		
2a) This action is FINAL. 2b) ☑ This	action is non-final.		
3) Since this application is in condition for allowan	ce except for formal matters, pro	secution as to the	merits is
closed in accordance with the practice under E	k parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.	
Disposition of Claims			
4) Claim(s) 11 and 15-21 is/are pending in the app	olication.		
4a) Of the above claim(s) is/are withdraw			
5) Claim(s) is/are allowed.			
6)⊠ Claim(s) 11 and 15-21 is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction and/or	election requirement		
are subject to resultation arising	olodion requirement.		
Application Papers			
9) The specification is objected to by the Examiner			
10) The drawing(s) filed on is/are: a) acce	pted or b) objected to by the E	Examiner.	
Applicant may not request that any objection to the o	rawing(s) be held in abeyance. See	37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correction	on is required if the drawing(s) is obj	ected to. See 37 CF	R 1.121(d).
11)☐ The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PT	O-152.
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign	oriority under 35 U.S.C. § 119(a)	-(d) or (f).	
a) All b) Some * c) None of:			
<ol> <li>Certified copies of the priority documents</li> </ol>			
<ol><li>Certified copies of the priority documents</li></ol>			
<ol><li>Copies of the certified copies of the priori</li></ol>	-	d in this National	Stage
application from the International Bureau	(PCT Rule 17.2(a)).		
* See the attached detailed Office action for a list of	of the certified copies not receive	d.	
Attachment(s)	0	(DTO 440)	
Notice of References Cited (PTO-892)	4) Interview Summary	(F1O-413)	

ail Date	
М	nmary (PTO-413) Mail Date coval Fatert Application

Application/Control Number: 10/517,805

Art Unit: 1625

Claims 11 and 15-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Srimanth et al in view of Ferrara et al, US Patent 6455283,filed 3-10-1999.. The latter in the field of treatment of cancer teaches that a cell from a tumor of a patient in need of treatment can be contacted with a compound which is a drug candidate and the ability of that compound to inhibit VEGF production is measured. See col. 5, lines 44-67. See also col. 37 line 63 to col. 4, line 19. It of course also teaches that that high VEGF production is present in cancerous tumors. See col. 1, lines 35-39 and col. 1, lines 50-62.

See also col. 31, lines 30-33, especially "other drug candidates" in lines 32 and 33. See also col.6. The former teaches that the instant 3-heterocyclyl-coumarins are active against cancer cell. Thus it would have been obvious to test the instant compounds' inhibition of VEGF in a tumor cell of a patient in need of treatment

Claims 11 and 15-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Srimanth et al in view of Ferrara et al and Hirth et al. The last reference buttresses what is taught by Ferrara et al that level of VEGF production by cancer cells is a measure of their virulence.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon-Fri from 8 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on 571 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/517,805 Page 3

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/ Bernard Dentz/

Primary Examiner, Art Unit 1625